US Breast Cancer Drug Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
The pharmaceutical companies have recently been focusing increasingly on women's health. Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women population globally and accounts for almost 3 per cent of the causes of death in women. It has been estimated that one in every 12 women is most likely to develop breast cancer at some point in her life, owing to risk factors such as hormonal effects, age and genetic predisposition. According to the American Cancer Society (ACS), the cases of women with breast cancer accounts to more than 1 in 4 cancer patients in the US. It is further estimated that in 2013, close to 32,000 new cases of breast cancer are expected to be diagnosed and close to 40,000 people are expected to die from breast cancer. By 2020, the combined sales of emerging and new therapies would account for more than 25% of the overall market for breast cancer drug treatments.
“US Breast Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Breast Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Breast Cancer Drug Pipeline Analysis” research report:
The pharmaceutical companies have recently been focusing increasingly on women's health. Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women population globally and accounts for almost 3 per cent of the causes of death in women. It has been estimated that one in every 12 women is most likely to develop breast cancer at some point in her life, owing to risk factors such as hormonal effects, age and genetic predisposition. According to the American Cancer Society (ACS), the cases of women with breast cancer accounts to more than 1 in 4 cancer patients in the US. It is further estimated that in 2013, close to 32,000 new cases of breast cancer are expected to be diagnosed and close to 40,000 people are expected to die from breast cancer. By 2020, the combined sales of emerging and new therapies would account for more than 25% of the overall market for breast cancer drug treatments.
“US Breast Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Breast Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Breast Cancer Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 9
- Preclinical: 43
- Phase-I: 33
- Phase-I/II: 19
- Phase-II: 73
- Phase-II/III: 2
- Phase-III: 12
- Registered: 3
- Marketed: 28
1. US BREAST CANCER DRUG MARKET OVERVIEW
2. BREAST CANCER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Breast Cancer Drug Profile in Clinical Phase
3. BREAST CANCER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Breast Cancer Drug Profile in Clinical Phase
4. BREAST CANCER DRUG CLINICAL PHASE: PHASE-I
4.1 Overview
4.2 Breast Cancer Drug Profile in Clinical Phase
5. BREAST CANCER DRUG CLINICAL PHASE: PHASE-I/II
5.1 Overview
5.2 Breast Cancer Drug Profile in Clinical Phase
6. BREAST CANCER DRUG CLINICAL PHASE: PHASE-II
6.1 Overview
6.2 Breast Cancer Drug Profile in Clinical Phase
7. BREAST CANCER DRUG CLINICAL PHASE: PHASE-II/III
7.1 Overview
7.2 Breast Cancer Drug Profile in Clinical Phase
8. BREAST CANCER DRUG CLINICAL PHASE: PHASE-III
8.1 Overview
8.2 Breast Cancer Drug Profile in Clinical Phase
9. BREAST CANCER DRUG CLINICAL PHASE: REGISTERED
9.1 Overview
9.2 Breast Cancer Drug Profile in Clinical Phase
10. MARKETED DRUGS
10.1 Overview
10.2 Marketed Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
2. BREAST CANCER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Breast Cancer Drug Profile in Clinical Phase
3. BREAST CANCER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Breast Cancer Drug Profile in Clinical Phase
4. BREAST CANCER DRUG CLINICAL PHASE: PHASE-I
4.1 Overview
4.2 Breast Cancer Drug Profile in Clinical Phase
5. BREAST CANCER DRUG CLINICAL PHASE: PHASE-I/II
5.1 Overview
5.2 Breast Cancer Drug Profile in Clinical Phase
6. BREAST CANCER DRUG CLINICAL PHASE: PHASE-II
6.1 Overview
6.2 Breast Cancer Drug Profile in Clinical Phase
7. BREAST CANCER DRUG CLINICAL PHASE: PHASE-II/III
7.1 Overview
7.2 Breast Cancer Drug Profile in Clinical Phase
8. BREAST CANCER DRUG CLINICAL PHASE: PHASE-III
8.1 Overview
8.2 Breast Cancer Drug Profile in Clinical Phase
9. BREAST CANCER DRUG CLINICAL PHASE: REGISTERED
9.1 Overview
9.2 Breast Cancer Drug Profile in Clinical Phase
10. MARKETED DRUGS
10.1 Overview
10.2 Marketed Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class
- Mechanism of Action
- ATC Code
- Designated Brand Name
